anonymous
Guest
anonymous
Guest
According to a new R&D benchmarking study published by drug Discovery Today, AbbVie drugs have the lowest likelihood of approval.. I mean lower than even likes of Astellas that spends almost three times less than AbbVie. What a shame!!! Where is almost $8Bn per year going… besides licensing drugs that won't work and and acquiring companies that would contribute ZERO???????